FMR LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.

Quarter-by-quarter ownership
FMR LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$1,704
-42.3%
1,444
-31.0%
0.00%
Q2 2023$2,951
+16.5%
2,093
+24.0%
0.00%
Q1 2023$2,532
+176.7%
1,688
+115.9%
0.00%
Q4 2022$915
-8.5%
782
-23.2%
0.00%
Q3 2022$1,000
-88.9%
1,018
-81.2%
0.00%
Q2 2022$9,000
+350.0%
5,426
+222.6%
0.00%
Q1 2022$2,0001,682
+84000.0%
0.00%
Q4 2021$020.0%0.00%
Q3 2021$02
-60.0%
0.00%
Q2 2021$05
-99.0%
0.00%
Q4 2019$05000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders